With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Genetic Susceptibility to Pediatric Osteosarcoma and Interaction with Measures of Childhood Growth||Duke University / Kyle Walsh, Ph.D.||'A' Award Grants||2014||North Carolina|
|Investigating the Role of Genetic and Epigenetic Variation in Risk of Childhood Acute Lymphoblastic Leukemia in Down Syndrome||University of California San Francisco / Adam de Smith, Ph.D.||'A' Award Grants||2014||California|
|The Role of MST1 in Non-canonical Hippo Signaling in Rhabdomyosarcoma||Duke University / Lisa Crose, Ph.D.||'A' Award Grants||2014||North Carolina|
|A Novel Target for Neuroblastoma Treatment||Beckman Research Institute of City of Hope / Linda Malkas, Ph.D.||Reach Grants||2014||California|
|Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen||Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D.||Reach Grants||2014||New York|
|Identifying Novel Therapeutic Combinations with 131I-MIBG to Treat Relapsed and Refractory Neuroblastoma||The Regents of the University of California San Francisco / William Clay Gustafson, M.D., Ph.D.||Reach Grants||2014||California|
|Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias||National Cancer Institute / Andre Nussenzweig, Ph.D.||Reach Grants||2014||Maryland|
|DNA Methylation Inhibitor Therapy for Testicular Germ Cell Tumors||University of Illinois, Urbana-Champaign / Michael Spinella, Ph.D.||Reach Grants||2014||Illinois|
|Immunotherapy of Neuroblastoma with CAR.GD2 NKT Cells||Baylor College of Medicine / Leonid S. Metelitsa, M.D., Ph.D.||Bio-Therapeutic Impact Award||2014||Texas|
|Phase I Trial of Indoximod in Combination with Temozolomide-based Therapy for Children with Progressive Primary Brain Tumors||Georgia Health Sciences University Research Institute, Inc. / Theodore Johnson, M.D., Ph.D.||Bio-Therapeutic Impact Award||2014||Georgia|